Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

DNA Methylation Biomarkers in Cancer: Progress Towards Clinical Implementation


Bock,  Christoph
Computational Biology and Applied Algorithmics, MPI for Informatics, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Mikeska, T., Bock, C., Do, H., & Dobrovic, A. (2012). DNA Methylation Biomarkers in Cancer: Progress Towards Clinical Implementation. Expert Review of Molecular Diagnostics, 12(5), 473-487. doi:10.1586/erm.12.45.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0014-C824-4
Altered DNA methylation is ubiquitous in human cancers and specific methylation changes are often correlated with clinical features. DNA methylation biomarkers, which use those specific methylation changes, provide a range of opportunities for early detection, diagnosis, prognosis, therapeutic stratification and post-therapeutic monitoring. Here we review current approaches to developing and applying DNA methylation biomarkers in cancer therapy. We discuss the obstacles that have so far limited the routine use of DNA methylation biomarkers in clinical settings and describe ways in which these obstacles can be overcome. Finally, we summarize the current state of clinical implementation for some of the most widely studied and well-validated DNA methylation biomarkers, including SEPT9, VIM, SHOX2, PITX2 and MGMT.